Business
VALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS
VALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS\nCanada NewsWire\nMONTREAL, June 14, 2022\n\n\n\nQ2-22 revenues of $4.8 million, up 80% over Q2-21Q2-22 gross margins of $1.7 million, up 134% over Q2-21Canadian provincial public reimbursement now complete for Enerzair® Breezhaler® and Atectura® Breezhaler® with the addition of British Columbia and NewfoundlandTSX listing of common shares and warrantsEnerzair and Atectura demonstrating fast market penetration against established asthma brandsMONTREAL, June 14, 2022 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today reported its financial results for the second quarter ended April 30, 2022.\n\n \n \n \n \n \n \n\n \nQ2 and year to date 2022 Financial Highlights:\nQ2-22 revenues of $4.8 million compared to $2.6 million for Q2-21, up 80%Q2-22 gross margin of $1.7 million compared to $0.7 million for Q2-21 up 134%H1-22 revenues of $9.0 million compared to $4.5 million for H1-21 up 100%H1-22 gross margins of $3.1 million compared to $1.1 million for H1-21 up 180%Net loss of $5.1 million for Q2-22 compared to $1.9 million for Q2-21Q2-22 Adjusted EBITDA loss of $3.8 million compared to $1.1 million for Q2-21Q2-22 Net loss and EBITDA loss down 13% and 22% compared to prior Q1-22 quarter.Q2 2022 Business Highlights \nTSX listing of the 12% convertible unsecured subordinated debentures issued pursuant to the $15.0 million bought deal private placement closed on December 9, 2021 under the symbol \"VPH.DB\";Uplisting of the Company's common shares and warrants from the CSE and start of trading on the TSX as of market open on Tuesday March 29, 2022;Enerzair and Atectura accepted for listing and public reimbursement in Ontario, Manitoba, New Brunswick, Saskatchewan, PEI and with the NIHB and VAC federal programs;Listing and public reimbursement of Redesca™ in British Columbia completes ...